LINK WILLIAM J PHD sold $980K of TARS

LINK WILLIAM J PHD sold 12,500 shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $78.38 ($78.33–$80.01, $0.98M total) across 3 trades on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LINK WILLIAM J PHD
Published Sep 17, 2026, 8:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TARS
Bearish
medium confidence
Mentioned
$TARS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TARSBearishLow
01

Why it matters

The disclosed sale is the primary new fact; no prior public reporting.

02

Market read

Small insider sale with limited market impact.

03

What to watch

Potential upcoming clinical data could be the real driver of price movement.

Relevance 4/10Novelty 4/10Timing: filed Sep 17, 2026

Background

Form 4 filing discloses insider transactions; Tarsus Pharmaceuticals is a biotech listed on NASDAQ.

Company-level read

Ticker impact

$TARSBearishMedium confidence
Context

Director William J. Link sold 12,500 shares for $979,744 via a 10b5-1 plan.

Expected impact

Potential modest downward pressure over next few days.

Evidence & confidence

Sale size is modest (~$1M) and executed under a pre-arranged plan, limiting informational value.

Market effects

Minimal impact on biotech sector; typical insider sales.

None

Low

Counterpoint

Sale may be routine; investors could ignore and focus on pipeline.

Key entities

  • Tarsus Pharmaceuticals, Inc.

    Biotech firm developing therapies.

  • William J. Link

    Director of Tarsus Pharmaceuticals.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TARSHighAI 8/10

Tarsus (TARS) Q3 2026 Earnings Call Transcript

Tarsus (TARS) reported Q3 2026 net product sales of $194.6M for XDEMVY, up 64% YoY. The company raised full-year sales guidance to $715M-$730M. Key growth drivers include increased patient demand, broader ECP prescribing, and retreatment. Tarsus also discussed pipeline progress and acquisition integration.

$TARSMedAI 8/10

Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals (NASDAQ:TARS) increased its 2026 XDEMVY sales outlook to $715M-$730M, citing stronger demand and advertising returns. Q3 saw 20% sequential growth in high-prescribing eye care professionals. The company expects 2027 direct-to-consumer spending of $80M-$95M. Gross margin is projected at 93%, with SG&A and R&D expenses outlined. Pipeline updates include TP-03 launch in China and upcoming trials for TP-04, TP-05, and IRX-101.